XML 23 R15.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Collaboration, License and Option Agreements | 6 Months Ended
--- | ---
Jun. 30, 2024
Collaboration License And Option Agreements [Abstract] |
Collaboration, License and Option Agreements | 7. Collaboration, License and Option Agreements Global Co-Development and Collaboration Agreement with BeiGene In April 2019, the Company entered into a Global Co-Development and Collaboration agreement (the “BeiGene Collaboration”) with BeiGene, Ltd. and BeiGene Switzerland GmbH (collectively “BeiGene”), for the development, manufacturing and commercialization of evalstotug (BA3071). The BeiGene Collaboration was amended several times between 2019 and 2021 and the Company received a total of $25.0 million in non-refundable payments from BeiGene during that time. In November 2021, the BeiGene Collaboration was terminated, subject to survival of certain provisions, and BeiGene handed back rights to know-how and materials received under the amended BeiGene Collaboration. As a result, the Company is responsible for the global development and commercialization of evalstotug. As consideration for this amendment, the Company agreed to pay BeiGene mid-single digit royalties on sales worldwide and on a limited basis will share in any upfront and milestone payments received through a sublicense of evalstotug. The Company reclassified its then remaining $19.8 million of deferred revenue as a long-term liability which is expected to settle as licensing payments are made to BeiGene in accordance with the resulting amendment. In the event the license is terminated, the liability will be extinguished with no further payment to BeiGene. The Company did no t recognize any revenue related to the collaboration agreement with BeiGene during the three and six months ended June 30, 2024 and 2023, respectively. The Company had a $19.8 million Liability to Licensor as of June 30, 2024 and December 31, 2023, respectively. Collaboration and Supply Agreement with Bristol-Myers Squibb In January 2022, the Company and Bristol-Myers Squibb Company (“BMS”) entered into a clinical trial collaboration and supply agreement (the “BMS Agreement”). Under the terms of the BMS Agreement, BioAtla and BMS collaborate on clinical trials of separate combination therapies using two of BioAtla’s CAB ADCs, mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021), each in combination with Opdivo® (nivolumab), BMS’ proprietary anti-PD-1 monoclonal antibody product. The Company serves as the study sponsor of the scheduled studies and is responsible for costs associated with the trial execution. BMS provides Opdivo® clinical drug supply at no cost for the combination study trials. After the completion of the combination therapy trials, the Company is obligated to provide BMS with a final report of the data resulting from the trial. The BMS Agreement was amended in October 2022 to include additional territories for our mecbotamab vedotin and ozuriftamab vedotin combination study trials. There was no impact to the Company's financial results for the three and six months ended June 30, 2024 and 2023 as a result of this agreement.

X
- Definition Collaboration, license and option agreements. + References No definition available. + Details
Name: | bcab_CollaborationLicenseAndOptionAgreementsAbstract
Namespace Prefix: | bcab_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration, license and option agreements text block. + References No definition available. + Details
Name: | bcab_CollaborationLicenseAndOptionAgreementsTextBlock
Namespace Prefix: | bcab_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration